I had to make a correction and while at it, expound slightly.
In the City of Hope pilot trial, Leronlimab is administered subcutaneously, while the intensive chemotherapy is delivered directly to the liver via the hepatic artery.
This dual-delivery system is the ultimate "Board of Action" in oncology—it allows the chemotherapy to strike the tumor from the inside (via the hepatic artery) while the 700mg Mandate of Leronlimab surrounds the tumor microenvironment from the outside to Prime the Immune System for total Molecular Clearance. Kiss those CTCs goodbye.
1. The Confirmation of the Delivery System
As established in the 2026 Audit, the City of Hope protocol (led by Dr. Pashtoon Kasi) utilizes this specific synergy:
Leronlimab: Administered subcutaneously (SC) as a weekly 700mg dose. This ensures the molecule maintains a constant "Search Warrant" throughout the bloodstream and the tumor microenvironment.
Chemotherapy (HAI): Administered through a Hepatic Artery Infusion (HAI) pump. This delivery method optimizes the dose and time exposure of chemotherapy directly to liver tumor cells—where they receive their primary blood supply—while limiting systemic toxicity.
2. Why This Distinction Matters
The "failed time-tested strategy" of the past relied on systemic IV chemotherapy that often crashed the body before it could reach the "fortress" of the liver. The City of Hope approach is the clinical equivalent of a Bayesian Shift:
The Sledgehammer (HAI): By using the hepatic artery, investigators can deliver a high-concentration of drug to the liver disease, taking advantage of the anatomic dependence of metastatic tumors on arterial blood.
The Locksmith (Leronlimab): Because Leronlimab is subcutaneous, it doesn't compete for the same delivery "pipe." Instead, it works in parallel to uncloak the tumor (upregulating PD-L1 in 88% of cases) so that the HAI-delivered chemo can achieve maximum execution.
3. Solidarity in the 2026 Audit
The fact that this study is targeting treatment-naïve patients with disease confined to the liver is a groundbreaking development. It means we are applying the "Hammer" at the earliest possible window of opportunity. First.
The "Montefiore" Legacy: Just as the 2020 data proved Leronlimab could reduce circulating tumor cells in the most dire mTNBC cases, this City of Hope trial is proving that the 700mg dose can be safely paired with the most aggressive local-delivery methods available.
The Scoreboard: We are no longer debating whether Leronlimab works; we are perfecting the how. By combining subcutaneous Leronlimab with HAI chemotherapy, we are creating a pincer movement that the "Inexplicable Intervention" can no longer ignore.
The "weird ride" Figgs mentions nears its destination. By mastering the subcutaneous 700mg Mandate alongside the hepatic artery "Hammer," CytoDyn through City of Hope is providing a level of care that renders traditional oncology "niche" and obsolete. We aren't just treating the liver; we are reconstructing the patient's future.
The goods are in the house.
In the City of Hope pilot trial, Leronlimab is administered subcutaneously, while the intensive chemotherapy is delivered directly to the liver via the hepatic artery.
This dual-delivery system is the ultimate "Board of Action" in oncology—it allows the chemotherapy to strike the tumor from the inside (via the hepatic artery) while the 700mg Mandate of Leronlimab surrounds the tumor microenvironment from the outside to Prime the Immune System for total Molecular Clearance. Kiss those CTCs goodbye.
1. The Confirmation of the Delivery System
As established in the 2026 Audit, the City of Hope protocol (led by Dr. Pashtoon Kasi) utilizes this specific synergy:
Leronlimab: Administered subcutaneously (SC) as a weekly 700mg dose. This ensures the molecule maintains a constant "Search Warrant" throughout the bloodstream and the tumor microenvironment.
Chemotherapy (HAI): Administered through a Hepatic Artery Infusion (HAI) pump. This delivery method optimizes the dose and time exposure of chemotherapy directly to liver tumor cells—where they receive their primary blood supply—while limiting systemic toxicity.
2. Why This Distinction Matters
The "failed time-tested strategy" of the past relied on systemic IV chemotherapy that often crashed the body before it could reach the "fortress" of the liver. The City of Hope approach is the clinical equivalent of a Bayesian Shift:
The Sledgehammer (HAI): By using the hepatic artery, investigators can deliver a high-concentration of drug to the liver disease, taking advantage of the anatomic dependence of metastatic tumors on arterial blood.
The Locksmith (Leronlimab): Because Leronlimab is subcutaneous, it doesn't compete for the same delivery "pipe." Instead, it works in parallel to uncloak the tumor (upregulating PD-L1 in 88% of cases) so that the HAI-delivered chemo can achieve maximum execution.
3. Solidarity in the 2026 Audit
The fact that this study is targeting treatment-naïve patients with disease confined to the liver is a groundbreaking development. It means we are applying the "Hammer" at the earliest possible window of opportunity. First.
The "Montefiore" Legacy: Just as the 2020 data proved Leronlimab could reduce circulating tumor cells in the most dire mTNBC cases, this City of Hope trial is proving that the 700mg dose can be safely paired with the most aggressive local-delivery methods available.
The Scoreboard: We are no longer debating whether Leronlimab works; we are perfecting the how. By combining subcutaneous Leronlimab with HAI chemotherapy, we are creating a pincer movement that the "Inexplicable Intervention" can no longer ignore.
The "weird ride" Figgs mentions nears its destination. By mastering the subcutaneous 700mg Mandate alongside the hepatic artery "Hammer," CytoDyn through City of Hope is providing a level of care that renders traditional oncology "niche" and obsolete. We aren't just treating the liver; we are reconstructing the patient's future.
The goods are in the house.
17
